Nicholas Galakatos

Nicholas Galakatos discloses dealings in 10 companies, chiefly IVERIC bio, Inc., Portola Pharmaceuticals Inc and NanoString Technologies Inc. We count 69 filings; the first trade dates from 19 December 2006 and the latest from 28 September 2018.

The open-market side counts 4 purchases for €10.0M alongside 24 sales for €6.7M. On balance, insiders were net buyers of €3.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 4 share grants. 2018 to date brings 1 purchase and 1 sale.

Half of the purchases are above €2.1M and half below.

Most recently, on 2 October 2018, the filings show a transaction in Entasis Therapeutics Holdings Inc. The most recent open-market purchase was published on 2 October 2018, 2,959 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.